This study will examine the effect of the presence, language, and prominence of a disclosure communicating information related to a prescription drug’s accelerated approval in direct-to-consumer promotional materials. We plan to conduct one pretest (N = 385) and one main study (N = 633) not longer than 20 minutes, administered via Internet panel. We will vary the presence and prominence of the disclosure (e.g., varying the presence, size, color, and location of the disclosure) on a website for a fictitious prescription drug. Participants will view the website and then answer questions about the drug information, including the disclosure.
The latest form for Experimental Study of an Accelerated Approval Disclosure expires 2020-06-30 and can be found here.
Approved without change
|No material or nonsubstantive change to a currently approved collection||2019-09-12|
Approved with change
|New collection (Request for a new OMB Control Number)||2019-05-09|
Federal Enterprise Architecture: Health - Consumer Health and Safety